Omeros Q2 YARTEMLEA Revenue Jumps 190%, Net Income Hits $13.2M
OMER has more than doubled off its 52-week low of $3.94.
Summary
Omeros reported Q2 2026 results with YARTEMLEA net revenue surging 190% quarter-over-quarter, driving net income of $13.2 million and non-GAAP adjusted net income of $1.8 million. The company also repurchased $30.5 million in convertible notes and $5.7 million in shares during the quarter, continuing its deleveraging and anti-dilution efforts. Management attributed the revenue growth to strong demand and positive physician feedback for YARTEMLEA, its only FDA-approved treatment for TA-TMA, and noted a reimbursement from Novo Nordisk for zaltenibart inventory transfer. Looking ahead, Omeros expects to begin enrollment in two YARTEMLEA studies and the OMS527 inpatient trial by year-end 2026, with a Phase 1b trial for OMS805 targeted for late 2027. This follows the CMS NTAP designation for YARTEMLEA announced earlier this month, which should further support reimbursement and adoption.
At the time of this announcement, OMER was trading at $15.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $992.3M. The 52-week trading range was $3.94 to $17.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.